PTAB Whiplash: Predictability, Policy and the PTAB Pendulum

This week on IPWatchdog Unleashed, I speak with Todd Walters, who is Chair of the Patent Office Litigation practice group at Buchanan. We explore the current state of Patent Trial and Appeal Board (PTAB) practice and the growing tension among stakeholders as policy changes continue to reshape post-grant proceedings. We reflect on the intensity of opinion from patent owners and petitioners and discuss the high financial stakes and strategic importance of AIA proceedings.

CAFC Partially Reverses Abiomed Patent Win, Revives Maquet Infringement Claims

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Monday issued a decision that affirmed in part, vacated in part, and remanded a ruling from the U.S. District Court for the District of Massachusetts in a patent dispute between Maquet Cardiovascular LLC and Abiomed Inc. The Federal Circuit agreed with the lower court that certain claims of one Maquet patent were not infringed by Abiomed’s Impella heart pumps, but revived Maquet’s infringement allegations on five other patents after finding the district court had improperly construed key claim terms.

Netflix Scores Win at CAFC in Reversal of 101 Decision for Patent Owner

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Monday in part reversed a district court’s decision upholding GoTV Streaming, LLC’s patents as eligible, finding instead that they were invalid under Section 101. While the opinion, authored by Judge Taranto, also reversed the district court’s finding that the claims were invalid for indefiniteness, the panel found they were directed to an abstract idea and therefore vacated the district court’s summary judgment of no inducement and its denial of GoTV’s motion for a new trial on damages, ordering the district court to enter judgment for Netflix, Inc., ending the case.

Federal Circuit Finds In-Store Product Locator Patents Ineligible as Abstract

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday affirmed a district court’s summary judgment ruling that six patents owned by Innovaport LLC are invalid for claiming ineligible subject matter under 35 U.S.C. § 101. The Federal Circuit agreed that the patents, which are directed to systems and methods for providing in-store product location information, claimed an abstract idea without adding a sufficient inventive concept to make them patent-eligible.

How Temu Works With Brands to Protect Intellectual Property Rights

When Temu launched in September 2022, it set out to connect consumers with sellers offering quality, affordable products. Today, the platform has built out a comprehensive system to keep counterfeit goods at bay. The number of brands Temu actively scans for fakes has grown from 3,000 to more than 5,000 over the past year. Temu now resolves more than 99% of requests to remove unauthorized products within three business days—most in under 24 hours. 

Patent Portfolio Economics: Balancing Quality, Cost and Market Coverage

Patent portfolios are frequently discussed in terms of size, technological breadth, or litigation potential. Those characteristics may be easy to measure, but they are not what determines whether a portfolio succeeds or fails. At their core, patent portfolios are business assets that must be managed deliberately and strategically. When they are not, they become cost centers that quietly consume resources without delivering meaningful competitive advantage.

Other Barks & Bites for Friday, February 6: Counterfeit Study Shows 41% Fail Product Safety Standards; USPTO De-Designates PTAB Precedentials on RPI Amendments

This week in Other Barks & Bites: Senator Ted Cruz (R-TX) calls for a federal framework for deploying self-driving cars to replace the state patchwork negatively impacting U.S. dominance in the field; a major apparel industry organization releases a study showing that nearly half of counterfeit products test positively for high levels of hazardous chemicals; Novartis issues guidance calling for its first annual operating profit loss in a decade due to patent expirations to blockbusters Entresto and Xolair; and more.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates